VERONICA FELAN: Open Payments
NPI 1609559624 · SUGAR LAND, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,381 in 63 payments from 16 companies in 2025. Trend: 2023 $477 · 2024 $719 · 2025 $1,381
Food & beverage: $1,282Education: $99
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 9 | $209 |
| Novo Nordisk Inc | 10 | $187 |
| Neurocrine BioSciences, Inc. | 6 | $180 |
| ABBVIE INC. | 9 | $174 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $125 |
| Gilead Sciences, Inc. | 1 | $99 |
| Amgen Inc. | 5 | $82 |
| Corcept Therapeutics | 3 | $72 |
| GlaxoSmithKline, LLC. | 3 | $52 |
| Sumitomo Pharma America, Inc. | 2 | $43 |
Products named: INGREZZA, QULIPTA, FARXIGA, Ozempic, Kerendia, Trodelvy, Korlym, BREZTRI.
Industry payments across TX — which companies pay providers there.
